Skip to main content

Table 5 Step 3. Adjusted models of the association linking patients’ SEP to receiving non-intensive therapy (n = 405)

From: Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients

  Model 3.0 (M3.0) Model 3.1 Model 3.2 Model 3.3
M3.0 + perf. Status M3.0 + WBC Fully adjusted
OR [95% CI] OR [95% CI] OR [95% CI] OR [95% CI]
Age 0.94 [0.91; 0.97] 0.96 [0.92; 0.99] 0.95 [0.92; 0.98] 0.96 [0.93; 0.99]
Sex Men ref   ref   ref   ref  
Women 1.39 [0.88; 2.20] 1.56 [0.96; 2.52] 1.41 [0.88; 2.25] 1.56 [0.96; 2.55]
Patients’ SEP (quintile of deprivation score) Q1 – least ref   ref   ref   ref  
Q2 1.02 [0.50; 2.09] 0.89 [0.42; 1.89] 0.94 [0.45; 1.98] 0.85 [0.40; 1.84]
Q3 1.09 [0.54; 2.20] 1.05 [0.50; 2.21] 1.07 [0.52; 2.19] 1.06 [0.50; 2.26]
Q4 1.12 [0.56; 2.25] 1.04 [0.51; 2.13] 1.04 [0.51; 2.12] 1.00 [0.48; 2.08]
Q5 – most 1.05 [0.51; 2.17] 1.05 [0.50; 2.22] 1.06 [0.50; 2.24] 1.07 [0.50; 2.32]
Charlson comorbidity index 0 ref   ref   ref   ref  
1 0.42 [0.23; 0.75] 0.47 [0.26; 0.86] 0.43 [0.23; 0.77] 0.47 [0.25; 0.86]
2+ 0.43 [0.23; 0.80] 0.51 [0.27; 0.98] 0.42 [0.22; 0.79] 0.49 [0.25; 0.94]
Undefinable 0.10 [0.06; 0.20] 0.15 [0.07; 0.29] 0.12 [0.06; 0.22] 0.15 [0.08; 0.31]
Performance status 0/1    ref     ref  
2    0.88 [0.46; 1.68]    0.92 [0.48; 1.79]
3/4    0.21 [0.10; 0.45]    0.24 [0.11; 0.52]
Undefinable    0.36 [0.20; 0.65]    0.41 [0.22; 0.76]
White blood cell (WBS) counts (tercile) Tercile 1 – low      ref   ref  
Tercile 2 – intermediate      0.76 [0.44; 1.30] 0.85 [0.49; 1.49]
Tercile 3 – high     0.41 [0.23; 0.72] 0.51 [0.28; 0.92]
Undefinable     0.13 [0.03; 0.71] 0.16 [0.03; 0.93]
  1. Population is selected among those who were not considered for intensive chemotherapy. Generalized linear model with logit link function, adjusted odds ratios [95% Confidence Intervals]